Stemina Biomarker Discovery, ILS Partner, Awarded $10 Million EPA Contract

RESEARCH TRIANGLE PARK, N.C.--Integrated Laboratory Systems, Inc. (ILS) partner Stemina Biomarker Discovery, Inc. (Stemina) announced this month that it has been awarded a contract by the United States Environmental Protection Agency entitled, “Developmental Toxicity Models for the ToxCast™ Compound Library.”  ILS is a subcontractor to Stemina on this contract and will be responsible for cell culture and genomic assays to supplement data from the metabolomic studies offered by Stemina. Under this contract, valued at over $10.5 million, drugs and chemicals will be screened using Stemina’s devTOX™ assay, a screening assay that utilizes human stem cells and metabolomics to identify compounds with the potential to cause birth defects if pregnant women are exposed. By integrating gene expression profiling with metabolomics, Stemina and ILS have together developed a comprehensive solution for identifying potential reproductive and developmental toxicants.
According to ILS Chief Scientist, Dr. Leslie Recio, “Using this integrated approach, the devTOX™ assay will be expanded to provide not only a developmental toxicology screening assay with information on the metabolic pathways perturbed by the test compound, but also a mode-of-action investigative toxicology platform to assess the potential impact of toxicants on the human genome and epigenome.”

ToxCast™ is a multi-year effort launched in 2007 at the EPA that uses high-throughput screening assays to assess the effects of chemical and drug exposure on living cells or isolated proteins. These innovative methods have the potential to limit the number of required laboratory animal-based toxicity tests while quickly and efficiently screening large numbers of chemicals. To date, over 2,000 chemicals from a wide range of classes and sources have been evaluated in ToxCast™.

About Stemina
Stemina is a biomarker discovery company which uses its metabolomics platform technology to develop and commercialize biomarker based toxicology tests for predicting the safety of agri-chemicals, industrial chemicals, consumer products and pharmaceutical compounds. In addition, Stemina is developing tests to diagnose autism from a blood sample to allow physicians to make personalized treatment recommendations for patients with autism based on the patient’s own biochemistry. Stemina was founded in 2007 and is located in Madison, Wisconsin.

About ILS
ILS is a leading life sciences services company that provides research support to federal and commercial clients. Among ILS’ core capabilities are investigative toxicology, genetic toxicology, genomics, molecular biology, histopathology, and environmental and information science services. These services are provided to a host of clients, including the National Institute of Environmental Health Sciences, National Toxicology Program, the National Cancer Institute, the U.S. Environmental Protection Agency, the U.S. Army, and numerous clients in the chemical and pharmaceutical markets. Based in Research Triangle Park, NC, ILS was founded by Chairman Dr. Thomas K. Rao in 1985. In 2013, ILS was a recipient of the Triangle Business Journal’s Life Sciences Best CRO Award, and recognized by Carolina Parenting for the ninth time as a NC Family-Friendly 50 company.  For more information please visit http://www.ils-inc.com.